Fewer regulatory snags in FY16 for Indian firms: report
This article was originally published in Scrip
Executive Summary
Indian drug firms may face fewer regulatory hurdles in FY16, in light ofstrengthened quality and control processes. Double digit export growth is likely, led by fully operational US FDA sites on restored regulatory approvals, according to a report by Fitch group company, India Ratings & Research (Ind-Ra).